https://www.streetinsider.com/Hot+M+and+A/Weber+%28WEBR%29+Receives+Takeover+Approach+-+Source/20688288.html
GSK Announced Jemperli RUBY Phase III Trial Met Primary Endpoint in Planned Interim Analysis in Patients With Primary Advanced or Recurrent Endometrial Cancer
GSK plc (LSE/NYSE: GSK) today announced positive headline results from the planned interim analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by Jemperli compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometria
